Pancreatic Cancer Research

ResearcherUniversity of LeedsNo recent work listed

Alan Anthoney

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5695-8312; OpenAlex author ID A5080693514. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: none · 2017: 1 paper · 2018: 3 papers · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper

Papers 12

  1. Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemothera… Last author DOI 10.1080/0284186x.2022.2053198↗
  2. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Co-author DOI 10.3390/cancers13225758↗
  3. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-020-0846-2↗
  4. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. Co-author DOI 10.1001/jamasurg.2019.3337↗
  5. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002557↗
  6. Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic ca… Co-author DOI 10.3892/ijo.2018.4640↗
  7. A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2017.495↗
  8. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0004-2↗
  9. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pa… Co-author DOI 10.1038/s41416-018-0005-1↗
  10. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-lab… Co-author DOI 10.1016/s0140-6736(16)32409-6↗
  11. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an … Co-author DOI 10.1016/s1470-2045(14)70236-0↗
  12. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. Co-author DOI 10.1093/jnci/djt347↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juan W. Valle · 10 shared papers, 2014–2022 · strength 0.64
  2. Daniel H. Palmer · 9 shared papers, 2014–2021 · strength 0.54
  3. John P. Neoptolemos · 8 shared papers, 2014–2021 · strength 0.43
  4. Paula Ghaneh · 7 shared papers, 2014–2021 · strength 0.40
  5. Bengt L. G. Glimelius · 7 shared papers, 2014–2021 · strength 0.40
  6. Christopher Michael Halloran · 7 shared papers, 2014–2021 · strength 0.40
  7. Julia V. Mayerle · 6 shared papers, 2014–2021 · strength 0.36
  8. Markus Wolfgang Büchler · 6 shared papers, 2014–2021 · strength 0.35
  9. Markus M. Lerch · 5 shared papers, 2018–2021 · strength 0.33
  10. Niall Christopher Tebbutt · 5 shared papers, 2014–2021 · strength 0.30
  11. David Goldstein · 4 shared papers, 2018–2021 · strength 0.27
  12. William Greenhalf · 5 shared papers, 2014–2021 · strength 0.26
  13. Eithne Costello · 5 shared papers, 2014–2021 · strength 0.26
  14. Richard Charnley · 4 shared papers, 2014–2021 · strength 0.23
  15. David Cunningham · 4 shared papers, 2014–2021 · strength 0.23
  16. Konstantinos Vellios Kamposioras · 2 shared papers, 2019–2022 · strength 0.21
  17. Nils O. Elander · 3 shared papers, 2018–2021 · strength 0.21
  18. Karen Aughton · 3 shared papers, 2018–2021 · strength 0.21
  19. Christos Dervenis · 4 shared papers, 2014–2019 · strength 0.20
  20. Attila Oláh · 4 shared papers, 2014–2019 · strength 0.20
  21. Thilo Hackert · 3 shared papers, 2017–2021 · strength 0.20
  22. Harpreet Singh Wasan · 3 shared papers, 2017–2020 · strength 0.18
  23. Derek A O'Reilly · 3 shared papers, 2017–2019 · strength 0.17
  24. Jakob Robert Izbicki · 3 shared papers, 2017–2019 · strength 0.17
  25. David J. Propper · 3 shared papers, 2014–2020 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.